We are live on !
Find out more
Soleus Capital Management Portfolio holdings
AUM
$2.9B
Turnover
33.33%
1-Year Est. Return
169.69%
This Fund
S&P 500
This Quarter Est. Return
+26.15%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$2.9B
AUM Growth
+$433M
(+18%)
Cap. Flow
-$46.5M
Cap. Flow % of AUM
Cap. Flow %
-1.6%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
114
New
21
Increased
25
Reduced
41
Closed
17
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insulet
PODD
|
+$81.1M |
| 2 |
Inspire Medical Systems
INSP
|
+$64.3M |
| 3 |
Rigel Pharmaceuticals
RIGL
|
+$56.6M |
| 4 |
Celcuity
CELC
|
+$48.5M |
| 5 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$40.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Twist Bioscience
TWST
|
+$73M |
| 2 |
Krystal Biotech
KRYS
|
+$63.9M |
| 3 |
Praxis Precision Medicines
PRAX
|
+$48.4M |
| 4 |
TG Therapeutics
TGTX
|
+$45.1M |
| 5 |
Vericel Corp
VCEL
|
+$39.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$9.5B
| $349M | 12.03% |
939,254
-213,833
| -19% | -$63.9M |
2020 Q4
22 quarters
|
|
|
2
Celcuity
CELC
$3.01B
| $178M | 6.14% |
1,704,318
+419,940
| +33% | +$48.5M |
2021 Q2
20 quarters
|
|
|
3
TG Therapeutics
TGTX
$8.11B
| $161M | 5.54% |
2,927,895
-1,101,424
| -27% | -$45.1M |
2022 Q4
14 quarters
|
|
|
4
Insulet
PODD
$9.9B
| $160M | 5.5% |
1,049,000
+486,500
| +86% | +$81.1M |
2025 Q4
2 quarters
|
|
5
NovoCure
NVCR
$1.83B
| $150M | 5.18% |
9,913,401
-578,990
| -6% | -$8.76M |
2024 Q4
6 quarters
|
|
6
United Therapeutics
UTHR
$24.2B
| $122M | 4.21% |
225,587
+38,400
| +21% | +$21.6M |
2021 Q3
19 quarters
|
|
|
7
Inspire Medical Systems
INSP
$2.05B
| $86.2M | 2.97% |
1,931,436
+1,355,137
| +235% | +$64.3M |
2025 Q1
5 quarters
|
|
|
8
Rigel Pharmaceuticals
RIGL
$912M
| $72.1M | 2.49% |
1,843,504
+1,833,504
| +18,335% | +$56.6M |
2023 Q1
13 quarters
|
|
9
ANI Pharmaceuticals
ANIP
$1.66B
| $71.8M | 2.48% |
867,760
+47,517
| +6% | +$3.81M |
2024 Q3
7 quarters
|
|
10
Beta Bionics
BBNX
$984M
| $68.8M | 2.37% |
4,393,714
+39,213
| +0.9% | +$466K |
2025 Q1
5 quarters
|
|
|
11
Vericel Corp
VCEL
$2.09B
| $64.9M | 2.24% |
1,459,152
-1,089,927
| -43% | -$39.2M |
2025 Q2
4 quarters
|
|
|
12
Praxis Precision Medicines
PRAX
$7.23B
| $59.4M | 2.05% |
177,517
-153,000
| -46% | -$48.4M |
2024 Q1
9 quarters
|
|
13
Geron
GERN
$745M
| $54.8M | 1.89% |
42,808,659
+1,300,000
| +3% | +$1.83M |
2025 Q1
5 quarters
|
|
14
Alkermes
ALKS
$7.34B
| $53.9M | 1.86% |
1,029,252
-941,612
| -48% | -$36.8M |
2025 Q4
2 quarters
|
|
15
Erasca
ERAS
$5.09B
| $49.5M | 1.7% |
+2,700,000
| New | +$38.6M |
2026 Q2
0 quarters
|
|
16
Neuropace
NPCE
$451M
| $46.3M | 1.59% |
2,911,122
-21,085
| -0.7% | -$339K |
2021 Q2
20 quarters
|
|
17
Progyny
PGNY
$2.19B
| $46.2M | 1.59% |
1,602,000
-465,000
| -22% | -$10.4M |
2026 Q1
1 quarter
|
|
18
Indivior Pharmaceuticals
INDV
$4.11B
| $43.7M | 1.5% |
1,064,000
-210,000
| -16% | -$7.62M |
2025 Q3
3 quarters
|
|
|
PBLS
19
Parabilis Medicines Inc
PBLS
$3.43B
| $40.1M | 1.38% |
+1,465,070
| New | +$40.5M |
2026 Q2
0 quarters
|
|
20
EDAP TMS S.A.
FOCL
$207M
| $37.9M | 1.3% |
7,309,254
| – | – |
2021 Q1
21 quarters
|
|
21
Globus Medical
GMED
$10.5B
| $37M | 1.28% |
468,922
-260,545
| -36% | -$22.1M |
2025 Q3
3 quarters
|
|
22
Arcus Biosciences
RCUS
$2.44B
| $36M | 1.24% |
1,168,738
+716,755
| +159% | +$17.7M |
2025 Q4
2 quarters
|
|
23
Syndax Pharmaceuticals
SNDX
$1.18B
| $35.6M | 1.23% |
1,628,039
-98,869
| -6% | -$2.06M |
2022 Q4
14 quarters
|
|
24
Nurix Therapeutics
NRIX
$2.85B
| $35.5M | 1.22% |
1,465,163
+527,000
| +56% | +$8.98M |
2023 Q3
11 quarters
|
|
25
Legend Biotech
LEGN
$3.62B
| $34.8M | 1.2% |
+1,205,000
| New | +$32.5M |
2026 Q2
0 quarters
|
|
Similar funds
Soleus Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Soleus Capital Management held 114 positions worth $2.9B, up 18% from $2.47B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Soleus Capital Management's Q2 2026 filing shows 21 new, 25 increased, 41 reduced and 17 closed positions. Its largest new stake was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M. The largest sale was Twist Bioscience, an estimated $73M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Soleus Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 1,465,070 shares worth $40.1M.
- Soleus Capital Management added most to Insulet in Q2 2026, an estimated $81.1M increase.
- Soleus Capital Management's biggest Q2 2026 reduction was Twist Bioscience, cutting an estimated $73M.
- Soleus Capital Management fully exited Vaxcyte in Q2 2026, selling an estimated $22.4M.
- Soleus Capital Management's ten largest holdings make up 49% of its $2.9B portfolio in Q2 2026.
- Soleus Capital Management opened 21 new positions and closed 17 in Q2 2026.
- Soleus Capital Management's portfolio value rose 18% quarter-over-quarter to $2.9B.
Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.